•  
  •  
image-724033-EliLillyLogo_250287_M.png
image-724106-Daybreak_Logo.png



I8D-MC-AZET


What follows is a brief summary of the Lilly DAYBREAK trial of a beta-secretase inhibitor designed to slow down the progression of disease for individuals with mild Alzheimer's due to Alzheimer's. 

  • Drug administration -- daily oral      

  • Age range -- 50-85

  • MMSE range -- 18-26

  • Study Duration -- 18 mos. + 18 month (opt.) extension

  • Target population -- Mild dementia                                                                         

  • Mechanism of action -- blocks formation of active beta amyloid protein (BACE inhibition)

  • Randomization split -- 1:1,  active:placebo

  • Type(s) of imaging -- brain MRI, amyloid PET


For more details on this specific trial, visit:


                                                                                      ClinicalTrials.gov

  A service of the U.S. National Institutes of Health

Donald S. Marks, M.D., P.C. -- 45 Resnik Road, Suite 205 -- Plymouth, MA, 02360

Tel: (508) 746-5060   Fax: (508) 746-8060